Expansion Therapeutics

Drugging RNA was once considered impossible. Now Big Pharma can't get enough of it - endpts.com/drugging-rna-w…

Scientists behind RNA-repairing strategy recognized with American Chemical Society’s Nobel Signature award eurekalert.org/news-releases/…

Expansion Therapeutics Raises $80 Million Series B Financing to Treat Neurodegenerative Diseases | Business Wire businesswire.com/news/home/2021…

Welcome Renato Skerlj, Ph.D., to the Expansion team! Renato brings more than 25 years of relevant experience advancing small molecule drugs for the treatment of rare diseases.

Expansion Therapeutics Names Renato Skerlj, Ph.D., Chief Executive Officer and President: expansionrx.com/news/renato-sk…

Congratulations to Expansion's Matthew D. Disney on being awarded a prestigious @NINDSnews grant to advance novel, RNA-targeting approaches for hard-to-treat brain diseases including Alzheimer's, Parkinson's, ALS, and others: scripps.edu/news-and-event… @disney_lab @scrippsresearch

Our initial disease focus is myotonic dystrophy type 1 (DM1), the most frequent cause of adult onset muscular dystrophy. To date, there is no disease-modifying therapy that exists for this rare disease: expansionrx.com/dm1/ #RareDiseaseDay #MyotonicDystrophy

As many as 1 in 20 people will live with a rare disease at some point in their life. Despite this, there is no cure for the majority of rare diseases and many go undiagnosed. Learn more at: rarediseases.org #RareDiseaseDay

Small molecules targeting mRNAs encoding “undruggable” proteins inhibiting their translation is a potential therapeutic strategy - RNA-targeting strategy successfully blocks a vexing driver of Parkinson’s disease | Scripps Research scripps.edu/news-and-event…

The inaugural "RNA: From Biology to Drug Discovery" symposium was a smashing success, bringing together scientists and innovators developing the next generation of RNA therapeutics @scrippsresearch @disney_lab #RNADay2019

Virtually all known drugs work on cell proteins. But Scripps Research’s @disney_lab targets the molecular messengers of our genetic code, opening the door to a plethora of new therapies for hard-to-treat diseases. Learn more and register for RNA Day, Dec 5 ow.ly/9TjQ50xb7i0

Join Expansion's Matthew D. Disney and other world-class scientists in the field of RNA therapeutics at the inaugural "RNA: From Biology to Drug Discovery" symposium on December 5, 2019. Learn more or register at scripps.edu/rna-day/ #RNADay2019 @disney_lab

Expansion Therapeutics Expands Leadership Team with Two Key Appointments; Names World-Renowned Scientist Lynne E. Maquat, Ph.D., to its Scientific Advisory Board: expansionrx.com/news/expansion…

Expansion is a proud sponsor of the inaugural @scrippsresearch Frontiers in Chemical Biology Symposium that includes talks by National Medal of Science winner JoAnne Stubbe, 2018 Nobel Prize Winner @francesarnold, and Expansion's own @RonBreaker and @disney_lab.

We seek talented and enthusiastic employees who possess an entrepreneurial and collaborative spirit and embrace our mission of innovation. Learn more about our current career opportunities: expansionrx.com/contact/career…

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions: the-scientist.com/bio-business/s…

We're honored to be in the good company of other 2019 Xconomy Awards San Diego finalists: xconomy.com/xconomy-awards… @Xconomy

RNA plays a diverse role in cell biology and is implicated in many diseases, making it an attractive therapeutic target. In a new review, Expansion's Matthew D. Disney discusses the design and development of small molecules interacting with RNA (SMIRNA): pubs.acs.org/doi/pdf/10.102…

Our understanding of RNA has evolved considerably in recent years, driven by advances in molecular biology and efforts to catalogue all functional elements in the human genome, including elements that act at the protein and RNA levels: expansionrx.com/smirna/

With an RNA-binding small molecule that converts HER2-negative breast cancer cells into HER2-positive cells, Expansion's Matthew D. Disney's is pioneering a novel therapeutic approach for triple-negative breast and other hard to treat cancers: expansionrx.com/news/expansion…